Cullinan Oncology LLC
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. The company develops zipalertinib, a bioavailable small molecule in Phase 3 trial for the treatment of patients with non-small cell lung cancer; CLN-978, a T cell engager to treat systemic lupus erythematosus and rheumatoid arthritis; and CLN-619, a … Read more
Cullinan Oncology LLC (CGEM) - Net Assets
Latest net assets as of September 2025: $451.37 Million USD
Based on the latest financial reports, Cullinan Oncology LLC (CGEM) has net assets worth $451.37 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($484.13 Million) and total liabilities ($32.76 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $451.37 Million |
| % of Total Assets | 93.23% |
| Annual Growth Rate | N/A |
| 5-Year Change | 194.7% |
| 10-Year Change | N/A |
| Growth Volatility | 46.28 |
Cullinan Oncology LLC - Net Assets Trend (2012–2024)
This chart illustrates how Cullinan Oncology LLC's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cullinan Oncology LLC (2012–2024)
The table below shows the annual net assets of Cullinan Oncology LLC from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $590.33 Million | +30.06% |
| 2023-12-31 | $453.89 Million | -15.16% |
| 2022-12-31 | $535.03 Million | +25.78% |
| 2021-12-31 | $425.37 Million | +112.35% |
| 2020-12-31 | $200.31 Million | +601.93% |
| 2019-12-31 | $-39.91 Million | -93.26% |
| 2018-12-31 | $-20.65 Million | -3492.24% |
| 2016-12-31 | $-574.85K | +53.82% |
| 2015-12-31 | $-1.24 Million | -9.65% |
| 2014-12-31 | $-1.14 Million | -12.99% |
| 2013-12-31 | $-1.00 Million | -221.01% |
| 2012-12-31 | $-313.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cullinan Oncology LLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 36564410000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $6.00K | 0.00% |
| Other Comprehensive Income | $-133.00K | -0.02% |
| Other Components | $958.70 Million | 162.40% |
| Total Equity | $590.33 Million | 100.00% |
Cullinan Oncology LLC Competitors by Market Cap
The table below lists competitors of Cullinan Oncology LLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MD Pictures Tbk PT
JK:FILM
|
$605.87 Million |
|
Peab AB (publ)
ST:PEAB-B
|
$606.11 Million |
|
FAST RETAIL.CO.SP.HDR 1
F:FR7H
|
$606.12 Million |
|
Olam Group Limited
PINK:OLGPF
|
$606.12 Million |
|
Naruida Technology Co. Ltd. Cl A
SHG:688522
|
$605.85 Million |
|
KWS SAAT SE & Co. KGaA
PINK:KNKZF
|
$605.80 Million |
|
Boozt AB (publ)
PINK:BZTAF
|
$605.80 Million |
|
Guangdong Cellwise Microelectronics Co. Ltd.
SHG:688325
|
$605.77 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cullinan Oncology LLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 453,703,000 to 590,328,000, a change of 136,625,000 (30.1%).
- Net loss of 167,383,000 reduced equity.
- New share issuances of 262,652,000 increased equity.
- Other comprehensive income decreased equity by 4,000.
- Other factors increased equity by 41,360,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-167.38 Million | -28.35% |
| Share Issuances | $262.65 Million | +44.49% |
| Other Comprehensive Income | $-4.00K | -0.0% |
| Other Changes | $41.36 Million | +7.01% |
| Total Change | $- | 30.11% |
Book Value vs Market Value Analysis
This analysis compares Cullinan Oncology LLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.22x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-25.81 | $13.44 | x |
| 2019-12-31 | $-40.06 | $13.44 | x |
| 2020-12-31 | $4.57 | $13.44 | x |
| 2021-12-31 | $9.59 | $13.44 | x |
| 2022-12-31 | $11.47 | $13.44 | x |
| 2023-12-31 | $10.92 | $13.44 | x |
| 2024-12-31 | $10.98 | $13.44 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cullinan Oncology LLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -28.35%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.05x
- Recent ROE (-28.35%) is below the historical average (-7.47%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-604.19K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-17.01K |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $14.97K |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-259.22K |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.12 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-15.96 Million |
| 2020 | -25.55% | -268.43% | 0.09x | 1.08x | $-70.75 Million |
| 2021 | -15.30% | -343.35% | 0.04x | 1.03x | $-107.54 Million |
| 2022 | 20.79% | 0.00% | 0.00x | 1.05x | $57.71 Million |
| 2023 | -33.76% | 0.00% | 0.00x | 1.07x | $-198.53 Million |
| 2024 | -28.35% | 0.00% | 0.00x | 1.05x | $-226.42 Million |
Industry Comparison
This section compares Cullinan Oncology LLC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cullinan Oncology LLC (CGEM) | $451.37 Million | 0.00% | 0.07x | $605.86 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |